Abbott Laboratories

New York Stock Exchange
Back to all articles
Somewhat Bullish +50

Abbott Laboratories Q2 preview: Analysts see healthy growth backed by Exact Sciences acquisition

AI-generated analysis

📅 Abbott Laboratories (ABT) is due to report Q2 earnings on July 16 before market open.

💰 Analysts expect EPS to rise by 1.6% to $1.28 per share and revenue to increase by 12.4% to $12.52 billion.

📉 EPS estimates have mostly been revised downward while revenue estimates show mixed revisions among analysts.

🚀 Baird predicts MedTech revenue growth will accelerate to meet the low end of management's full-year guidance (6.5%-7.5%).

🩺 MedDevices segment is expected to achieve 8%-10% top-line growth due to the breadth of product offerings.

🤝 The acquisition of Exact Sciences is a major strategic move expected to boost short-to-medium-term revenues.

🧬 Exact's CancerGuard with Cologuard MCED test could grow revenue from ~$3bn toward or beyond $5bn annually.

📈 This growth depends on the market embracing the new multi-cancer early detection technology effectively.

Bullish Signals
  • Analysts expect healthy top- and bottom-line growth for Abbott Laboratories in the upcoming Q2 earnings report.
  • MedTech segment is predicted to accelerate revenue growth, potentially meeting the low end of management's full-year guidance.
  • MedDevices segment is forecasted to achieve 8%-10% top-line growth driven by a broad product portfolio.
  • The Exact Sciences acquisition offers significant upside potential, with revenue from the combined MCED test expected to grow from ~$3bn toward or beyond $5bn annually.
  • Management's full-year guidance for MedTech (6.5%-7.5%) appears achievable based on current analyst predictions.
Risk Factors
  • Revenue estimates show mixed revisions among analysts, suggesting uncertainty about the magnitude of top-line performance.
Full Analysis
Abbott Laboratories (ABT) is scheduled to report its second-quarter earnings on July 16, with analysts projecting healthy top-line and bottom-line growth. The market expects earnings per share (EPS) to increase by approximately 1.6% to reach $1.28 per share, while revenue is forecasted to rise by 12.4% to $12.52 billion. Analyst consensus indicates mixed revisions for the upcoming report, with EPS estimates trending downward despite revenue expectations showing varied adjustments. Baird specifically predicts that Abbott's MedTech segment will accelerate growth to meet the low end of management's full-year guidance range of 6.5% to 7.5%, while the MedDevices segment is expected to achieve top-line growth between 8% and 10%. A key driver for Abbott's future revenue potential is its acquisition of Exact Sciences, which aims to expand the company's market presence in colorectal cancer screening. The integration of Exact's CancerGuard with Cologuard MCED test is projected to boost short-to-medium-term revenues, potentially growing annual revenue from approximately $3 billion toward or beyond $5 billion if the market fully embraces the new multi-cancer early detection technology. Overall, the article highlights a positive outlook for Abbott Laboratories driven by strong segment performance and strategic acquisitions. Investors are watching closely how the company executes on its guidance amidst mixed analyst sentiment regarding specific earnings estimates.